Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience
نویسندگان
چکیده
Multiple myeloma (MM) is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression‐free survival (PFS), and overall survival (OS) of MM patients.[1,2] However, alongside these benefits, a significant increased risk of developing secondary primary malignancies (SPMs) has been observed. Until now, there has not been a relevant large study of Chinese MM patients available to study SPMs, and no secondary malignancy after bortezomib treatment alone has been reported.
منابع مشابه
درگیری پستان در فرد مبتلا به بیماری مولتیپل میلوما: گزارش موردی
In this paper, we report a rare case who is a twenty-six years old woman with extramedullary organ involvement of multiple myeloma. The initiation of disease was solitary plasmacytoma in the second vertebra of the lumbar spine that received radical radiotherapy and then she underwent chemotherapy for one year with the diagnosis of multiple myeloma after expanding lesion to the bones and adjacen...
متن کاملPersistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
PURPOSE This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years o...
متن کاملLong-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.
Multiple myeloma (MM) accounts for 1.5% of all cancers and approximately 13% of all hematologic malignancies. Therapy for MM has substantially improved after the application of immunomodulatory drugs and proteasome inhibitors. The first proteasome inhibitor, bortezomib, can be considered a major milestone in treatment of MM, greatly improving the response rates and overall survival in front-lin...
متن کاملCanadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
BACKGROUND Multiple myeloma (MM) is a cancer caused by malignant plasma cells that accumulate mostly in the bone marrow. In Canada, the most common maintenance therapy options after autologous stem cell transplant (ASCT) are bortezomib and lenalidomide. OBJECTIVE To determine the incremental cost between bortezomib and lenalidomide maintenance therapies for patients with MM post ASCT. METHO...
متن کامل